Financial News Discussion of CELG - Celgene Corporation on The Call

Financial News for Celgene Corporation (CELG)

CELG 3/19/2010 9:51AM 52 Week Price Range Market Capitalization Dividend Yield Recent Dividend
$65.18 $36.90 — $65.07 $29.9 Billion n/a n/a

Want to Sharpen Your Investing?

Learn how Ockham can help investors make informed decisions and slice through the noise. Learn more about Ockham's services.

Sign Up Now for Ockham's Stock Analysis and News Services

Explore Why Ockham?

Quality Analysis
Ockham has fundamental valuations on over 5000 companies which we distribute, to our clients via highly-focused equity reports, weekly newsletters, and analysts' daily market commentary blogs. (Learn More)
Crowd Sentiment
Through our partnership with The Motley Fool, Ockham provides the most robust data on investors' sentiment of individual stocks. This indicator, along with our valuations and our news tracking, helps our clients make informed investment decisions. (Learn More)
Financial News Slicing
With the influx of noise in our lives, it can be exceedingly difficult to separate the essential news from everything else. Ockham's RazorWire tool "slices" through business television and impactful blogs to provide you with the clearest information possible. (Learn More)
Celgene Corp. was discussed on The Call which was originally produced by CNBC on 12/18/2009
On 12/18/09 Celgene Corporation was mentioned on The Call. The exact context of the conversation can be found just below.

News has broken via the television and viral blogs regarding CELG, so investors should take an interest in learning what was said.

The Motley Fool CAPS data suggests that investors believe Celgene Corporation will beat the market in the foreseeable future. We noticed recently that in comparison to all other stocks we analyze in the news; CELG has received less coverage from the financial media in business television and blogs. Based on our methodology, Celgene Corporation should hold some appeal to value investors as we view it as Undervalued as of this week's report. With the price now up to $55.78, we may consider downgrading the stock's valuation coming into next week. The latest news on CELG has created quite a stir as the stock is trading $5.16 higher in today's session.

“2% so outpacing the market's gains in large part due to CELGENE up 10% because they stopped a big study early because patients with the blood cancer were doing so well on one of ...” The Call Dec 18, 2009 11:03 AM
Just a couple of things to take note of: